Bronchodilators Market Key Players Analyzed 2022

The rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma

The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others. Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease that causes breathlessness and predisposes to exacerbations and severe illness. According to the World Health Organization (WHO), around 251 million people suffer from Chronic obstructive pulmonary disease (COPD) worldwide. In addition, around 3.17 million people died due to Chronic obstructive pulmonary disease (COPD) worldwide.

As to the American Academy of Allergy Asthma and Immunology (AAAI), in 2016, about 8.3% of children in the US were found to have asthma. Boys were, to some size, more likely to have asthma than girls at a time of 9.2% and 7.4%, sequentially. Asthma rate among children grew from 8.7% in 2001 to 9.4% in 2010 and decreased to 8.3% in 2016. Although not all changes were statistically remarkable, a similar outline was observed among the sub-demographic groups, except the Mexican/Mexican-American children, among whom asthma predominance increased from 5.1% in 2001 to 6.5% in 2016. The substantial increase in prevalence and incidence of asthma and COPD has led to an increase in the patient population, which has, in turn, increased the demand for these bronchodilators.

Increasing Usage of Bronchodilators for the Treatment of Cystic Fibrosis

Increasing the usage of bronchodilators for the treatment of cystic fibrosis is increasing the growth of the bronchodilators market. Inhaled bronchodilators are prescribed for 80% of people with cystic fibrosis to widen the airways and alleviate symptoms. Long inhaled and short inhaled bronchodilators improve respiratory symptoms as they take effect in minutes and typically last for eight hours. Cystic Fibrosis patients take bronchodilators using a metered-dose inhaler as it ensures that they can breathe in a total dose of their medications. Short‐acting inhaled bronchodilators take effect in minutes and typically last for four to eight hours (muscarinic antagonists). Long‐acting inhaled bronchodilators also take effect within minutes but typically last for around 12 hours and sometimes longer. Cystic fibrosis is a life‐limiting inherited condition that affects one in 2500 newborns in the UK and 70,000 children and adults worldwide. These factors are driving the market growth in the forecast period.

R&D activities related to bronchodilators are anticipated to present new opportunities for the market

There are various companies, research organizations, and government agencies doing extensive R&D for novel medications to treat COPD and asthma. The bronchodilators are their main area of research.

For instance, 3rd International Research & Development press conference, Boehringer Ingelheim unveiled a pipeline of unique asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer compounds build on the company’s vast respiratory experience over many decades.

Research and development programs continue to progress year by year with a strong focus on respiratory disease. Respiratory is a core area of R&D expertise, which has delivered significant value for the company and continues to expand to meet unmet medical needs in asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases.

The government organization such as NCBI is also involved in the  research and development of medication for bronchodilators. As per clinicaltrials.gov, a 12-week treatment study is conducted to evaluate the effectiveness of Albuterol Multidose Dry Powder inhaler with integrated electronic module digital system (eMDPI DS) in patients 13 years or older with asthma (CONNECT1).

This is a 12-week treatment, multicenter, open-label, randomized, parallel-group comparison feasibility study to evaluate the effectiveness of the Albuterol MDI Digital System (DS), including an inhaler, App, DHP (Cloud solution), and dashboard, to optimize outcomes in patients at least 13 years of age or older with asthma.

The study will consist of a screening visit, a 12-week open-label treatment period, and a follow-up telephone call (2 weeks following treatment completion). Patients with suboptimal asthma control will be enrolled in the study and randomized in a 1:1 ratio to 1 of 2 parallel groups stratified by an investigational center.

Although the efficacy of inhaled long-acting bronchodilators has been well documented in randomized controlled studies, whether similar effects are obtained in real-life clinical practice is not clear. Thus these studies are conducted to analyze the effect of inhaled long-acting bronchodilators in newly-diagnosed asthma patients.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com